*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated
This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the
*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered
*May 2021* Dr. Heather Wakelee joins GRACE to discuss treatment options for a metastatic non small cell lung cancer diagnosis.
*April 2021* MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR
*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with
*May 2021* The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small
*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml
*April 2021* The FDA has granted a priority review designation to a new drug application (NDA) for mobocertinib (TAK-788) for
*May 2021* Tyrosine kinase inhibitors (TKIs) are a class of drugs used to treat patients with certain types of advanced-stage
